Date: 2011-06-09
Type of information: Completion of patient enrollment
phase: 3
Announcement: completion of patient enrollment
Company: Merck Serono, a Merck KGaA company (Germany)
Product: cilengitide
Action
mechanism: integrin inhibitor
Disease: glioblastoma
Therapeutic area: Cancer - Oncology
Country:
Trial
details: CENTRIC was designed to assess the efficacy and safety of the investigational integrin inhibitor cilengitide in combination with standard treatment in a biomarker-defined subgroup of newly diagnosed patients with glioblastoma. More than 500 patients have been successfully recruited into this global trial. The primary endpoint of the study is overall survival.
Latest
news: Merck KGaA announced that patient enrollment in the global pivotal Phase III clinical study CENTRIC(a) has been completed.
